ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Atezolizumab/Bevacizumab in Metastatic RCC Moves to Phase III Trial

Atezolizumab/Bevacizumab in Metastatic RCC Moves to Phase III Trial

 

In this video, Michael B. Atkins, MD, of Georgetown University in Washington, DC, discusses second-line data from the IMmotion150 trial.

The study initially tested first-line atezolizumab vs sunitinib vs atezolizumab plus bevacizumab in untreated patients with metastatic renal cell carcinoma, and demonstrated an improved progression-free survival for the atezolizumab/bevacizumab combination.

Atkins presented second-line results of the study (abstract 4505) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2–6 in Chicago.

By clicking Accept, you agree to become a member of the UBM Medica Community.